PANKU-Lung01
What it tests: Izalontamab brengitecan in EGFR-mutant non-squamous NSCLC after progression on a third-generation EGFR TKI

Listen to Oncology Here & Now
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletterWhat it tests: Izalontamab brengitecan in EGFR-mutant non-squamous NSCLC after progression on a third-generation EGFR TKI
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.